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Abstract
Abl kinases are prototypic cytoplasmic tyrosine kinases and are involved in a variety of chromosomal aberrations in different cancers. This causes the 
expression of Abl fusion proteins, such as Bcr-Abl, that are constitutively activated and drivers of tumorigenesis. Over the past decades, biochemical 
and functional studies on the molecular mechanisms of Abl regulation have gone hand in hand with progression of our structural understanding of 
autoinhibited and active Abl conformations. In parallel, Abl oncoproteins have become prime molecular targets for cancer therapy, using adenosine 
triphosphate (ATP)–competitive kinase inhibitors, such as imatinib. Abl-targeting drugs serve as a paradigm for our understanding of kinase inhibitor 
action, specificity, and resistance development. In this review article, I will review the molecular mechanisms that are responsible for the regulation of 
Abl kinase activity and how oncogenic Abl fusions signal. Furthermore, past and ongoing efforts to target Abl oncoproteins using ATP-competitive and 
allosteric inhibitors, as well as future possibilities using combination therapy, will be discussed.
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Structure and Regulation of Abl
The Abl family of cytoplasmic tyrosine 
kinases consists of 2 members, Abl and 
Arg (Abl-related gene), encoded by the 
ABL1 and ABL2 genes in humans, and 
has important roles in various biological 
processes.1,2 Abl kinases share a central 
SH2-kinase domain unit with the major-
ity of other cytoplasmic kinases3 and 
have a long C-terminal tail, termed the 
last exon region, that carries numerous 
protein-protein interaction sites (Fig. 
1).4 The activity of Abl kinases is regu-
lated by a complex set of intramolecular 
interactions that impinge on the Abl 
kinase domain and lead to effective inhi-
bition of tyrosine kinase activity both in 
vitro and in vivo. Even a partial, albeit 
persistent, disruption of autoinhibitory 
constraints results in oncogenic transfor-
mation. Kinase activity of the full-length 
Abl protein is low in vitro and hard to 
detect in unstimulated cells. In contrast, 
the isolated Abl kinase domain has a 
10- to 100-fold higher kinase activity 
than the full-length protein (unpublished 
observation). This indicates that the 
additional domains present in Abl 
kinases mediate both intra- and intermo-
lecular interactions that either directly or 
indirectly dampen catalytic activity of 
the kinase. The SH3 and SH2 domains 
of Abl play key roles in mediating auto-
inhibition and will therefore be dis-
cussed first.
Abl SH3 and SH2 Domains
SH3 and SH2 domains are, with more 
than 300 and 120 members, respectively, 
among the most common modular 
protein-protein interaction domains 
found in human proteins.5 SH3 domains 
bind to peptides forming polyproline 
type II helices, whereas SH2 domains 
bind to phosphotyrosine-containing pep-
tides. The Abl SH3 domain was the first 
SH3 domain that was crystallized with a 
bound ligand peptide and therefore 
revealed how the SH3 domain mediates 
protein-protein interactions (Fig. 1).6 
Likewise, the Abl SH2 domain was the 
first SH2 domain to be structurally char-
acterized and gave important insight 
into the folding and dynamics of the 
domain (Fig. 1).7 Based on these hall-
mark structures, fundamental principles 
of ligand recognition, specificity, and 
relation to other protein-protein interac-
tion domains were made in the follow-
ing years.5 The structural elucidation 
of the Abl SH3-SH2 dual domain con-
struct indicated flexible linkage of the 
2 domains without major interactions 
(Fig. 1).8
Abl Autoinhibition by Its SH3 and SH2 
Domains
It could be conclusively demonstrated 
that Abl is autoinhibited, and no other 
proteins that may serve cellular inhibitors 
need to be envisaged.9 A major role in 
mediating autoinhibition is attributed to 
the Abl SH2 and SH3 domains. Elegant 
biochemical work demonstrated an intra-
molecular interaction of the Abl SH3 
domain with its own SH2-kinase domain 
linker. This sandwiches this linker 
between the SH3 domain and the N- 
terminal lobe of the kinase domain (Fig. 
2). Perturbation of this network of inter-
actions strongly activated Abl kinase 
activity.10 The SH2-kinase linker adopts 
the conformation of a polyproline type II 
helix, which is the preferred ligand of the 
SH3 domain. This mechanism is con-
served in the Src kinases, which share the 
same domain organization and a high 
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sequence identity in the folded domains 
and domain linkers with the Abl kinases.
In contrast to the SH3 domain, the role 
of the SH2 domain in regulating Abl 
activity remained unclear much longer 
and turned out to be very different from 
Src kinases.11 The Src SH2 domain binds 
to the C-terminal tail of the kinase domain 
that is phosphorylated on a single tyro-
sine residue by the Csk kinase and 
thereby keeps Src in a closed/assembled 
conformation of low catalytic activity 
(Fig. 2).12-14 The long C-terminal last 
exon domain of Abl lacks a functional 
equivalent of the C-terminal phosphoty-
rosine in Src. Autoinhibted Abl is not 
phosphorylated on tyrosine residues, 
showing that the SH2 domain does not 
bind an intramolecular ligand. In addi-
tion, the analysis of SH2 domain dele-
tions or mutations in Abl and the 
oncogenic fusions v-Abl and Bcr-Abl did 
not unequivocally decipher the function 
of the SH2 domain for kinase activity and 
transformation.15-17 The determination of 
crystal structures of autoinhibited Abl 
and accompanying functional experi-
ments resolved most of this nebulos-
ity.18,19 The Abl SH2 domain forms an 
extensive interaction interface with the 
C-terminal lobe of the kinase domain that 
is stabilized by an interlocking network 
of hydrogen bonds (Fig. 2).18 Due to the 
different relative orientation of the 2 
kinase lobes in Src and Abl, the SH2 
domain approaches the kinase domain 
much closer in Abl (Fig. 2). The SH2–C-
lobe interface in autoinhibited Abl partly 
occludes access of phosphotyrosine 
ligands to the phosphotyrosine binding 
pocket (Fig. 2).18 This positioning also 
explains why phosphotyrosine ligands 
and high-affinity engineered Abl SH2 
binding proteins were able to stimulate 
kinase activity in vitro and in cells.19,20 
Most important, docking of the SH2 
domain to the C-lobe of the kinase is 
gated by the N-terminal myristate moiety 
that is bound to its binding pocket in the 
C-lobe.
Abl Regulation by Myristoylation
Abl and Arg have 2 alternatively spliced 
first exons, termed 1a and 1b in humans 
(type I and IV in mouse). The 1b splice 
form is 19 amino acids longer than Abl 1a 
and carries a myristate group, a saturated 
fatty acid with 14 carbon atoms, at its 
N-terminus. Protein N-myristoylation is 
implicated in targeting proteins to mem-
branes, but myristoylation alone is not 
sufficient for stable membrane binding. 
Dual myristoylation and palmitoylation 
or additional polybasic amino acid 
stretches that interact with negatively 
charged phospholipids at the inner leaflet 
of the plasma membrane are necessary 
for membrane targeting.21 In Abl 1b, nei-
ther of those 2 additional membrane 
Figure 1. Timeline of Abl structural insights. A schematic domain representation of Abl is shown on top of the figure. Below, the structures, staggered 
by the time when they were published, of the different Abl domains and domain combinations are shown in cartoon representation. The structures 
are colored as in the schematic domain representation on top. Once different structures of the same domains (e.g., obtained with different methods, 
different crystal forms, mutants, drugs) were published simultaneously, only one representative structure is shown for graphical convenience. The PDB 
entries from which the representations were derived are shown next to the respective structure.
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targeting signals are observed, and in line 
with this, only a minor fraction of Abl is 
localized at membrane-proximal sites. 
Overall, Abl has diverse localizations in 
the cytoplasm, nucleus, and a variety of 
intracellular organelles (reviewed in Pen-
dergast2). Furthermore, nonmyristoylated 
Abl was not differentially localized than 
the myristoylated protein.19 On the other 
hand, mutants defective in F-actin bind-
ing depleted membrane co-localized Abl, 
indicating that binding to the membrane-
proximal cortical F-actin cytoskeleton 
rather than myristoylation is a major 
determinant of membrane localization.22
In contrast, Abl myristoylation was 
found to be involved in regulating kinase 
activity. Mutants of Abl 1b that lack the 
myristoyl group show strongly deregu-
lated cellular and in vitro tyrosine kinase 
activity.19 A crystal structure of the 
kinase domain in complex with a myris-
toylated peptide corresponding to the 
very N-terminus of Abl 1b showed that 
the myristoyl group is buried in a deep 
hydrophobic pocket in the C-lobe of the 
kinase (Figs. 1 and 2).18 Myristoyl bind-
ing to this pocket causes a 90° bending 
of the C-terminal α-I helix of the kinase 
domain. Only this event creates the 
complete docking site for the SH2 
domain on the C-lobe and enables the 
assembly of the autoinhibited conforma-
tion of Abl 1b (Fig. 2). Mutations that 
block access to the myristate pocket 
strongly increase kinase activity.19 
Importantly, compounds binding to the 
myristate pocket act as allosteric Abl 
inhibitors (see below and reviewed in 
Hantschel23).
Kinase Domain Structures
Studies on the structure of the Abl kinase 
domain revealed important insight into 
the regulation of catalysis and recogni-
tion mode of Abl kinase inhibitors. Early 
work showed that Tyr-412 in the activa-
tion loop is a major autophosphorylation 
site and constitutes a switch between the 
inactive and active kinase conforma-
tion.24,25 Co-crystal structures of the 
kinase domain in complex with imatinib 
and other kinase inhibitors exemplified 
binding modes of drugs and associated 
conformational changes in the kinase 
domain (reviewed in O. Hantschel, 
F. Grebien, and G. Superti-Furga, unpub-
lished data; Fig. 1).26,27 Importantly, these 
structures were indispensable tools to 
rationalize the mechanism of action of 
point mutations causing drug resistance.28 
Structures in complex with adenosine 
triphosphate (ATP)–peptide conjugates 
showed a close structural resemblance to 
the inactive Src kinase domain (Fig. 1).29 
This conformation, termed Src-like inac-
tive conformation, together with addi-
tional crystal structures and molecular 
dynamics simulations exemplified con-
formational dynamics of the wild-type 
and mutant Abl kinase domain and its 
consequences for drug binding and 
specificity over the closely related Src 
kinases.29,30
Active Abl: The SH2-Kinase Interface
Upon activation, Abl undergoes exten-
sive domain rearrangements. One hall-
mark change is that the SH2 domain 
does not bind to the C-terminal lobe 
any more but forms an extensive inter-
face with the N-terminal lobe of the 
kinase domain.31,32 These intramolecular 
Figure 2. Structure of autoinhibited Abl and Src. Cartoon representation of autoinhibited Abl in 
complex with the adenosine triphosphate (ATP)–competitive inhibitor PD166326 (left; PDB entry 
1OPK, 18) compared with autoinhibited Src in complex with the ATP analogue AMP-PNP (right; 
PDB entry 2SRC, 14). Below the cartoon representations of the crystal structures, more schematic 
representation are used that should illustrate global conformation differences of the 2 kinases. In 
both kinases, the SH3-SH2 domain unit forms a clamp that inhibits the kinase domain. In Src, the 
tyrosine-phosphorylated tail binding to the SH2 domain latches the clamp. The myristoyl group of 
Abl serves as a latch for the SH3-SH2 clamp by inducing a conformational switch in the C-terminal 
kinase domain helix that gates clamp binding.
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interaction interfaces in autoinhibited Abl 
and active Abl involve different surfaces 
of the SH2 domain. The positioning of 
the SH2 domain on the N-lobe mediates 
allosteric activation of the kinase domain 
that is independent of its phosphotyrosine 
binding capability. This mechanism was 
also demonstrated in great structural and 
biochemical details for the tyrosine 
kinase Fes.32 Furthermore, indirect evi-
dence indicated that the SH2 domain in 
other cytoplasmic tyrosine kinases might 
also act as an allosteric activator, in line 
with the overall conservation of the SH2-
kinase domain unit in these tyrosine 
kinases. Most important, the SH2-kinase 
domain interface in the oncogenic fusion 
Bcr-Abl was recently shown to be essen-
tial for leukemogenicity and represent a 
novel allosteric target for pharmacologi-
cal intervention.33
In addition to its allosteric regulatory 
role, the positioning of the SH2 domain 
on the N-lobe facilitates multisite (pro-
cessive) phosphorylation of Abl sub-
strates with multiple phosphorylation 
sites by binding to prephosphorylated 
(primed) substrates.34 Mutation of the 
phosphotyrosine-binding pocket or its 
blockade by a high-affinity engineered 
protein antagonist impairs processive 
phosphorylation of the Abl substrate 
paxillin to the same extent as mutation 
of the SH2-kinase domain interface.20,33 
It is important to note that the substrate 
specificity of the Abl kinase domain is 
very similar to the ligand-binding pref-
erence of the Abl SH2 domain, which 
not only indicates the co-evolution of 
the 2 domains but also rationalizes the 
above-described mechanism.34,35
Mechanisms of Abl Activation
In addition to their role as intramolecu-
lar regulators of kinase activity, inter-
molecular binding of the SH3 and SH2 
domains to their respective ligands in a 
variety of interacting proteins and sub-
strates is disrupting the inhibitory inter-
actions. This appears to be a widely used 
mechanism of Abl activation.4 Likewise, 
phosphorylation of Abl by upstream 
kinases or autophosphorylation events 
lead to conformational changes that 
disrupt the intramolecular engagement of 
the SH3 and SH2 domains and trigger the 
formation of intermolecular protein-pro-
tein interactions.4 A well-documented 
example for this type of mechanism is 
phosphorylation of Tyr-245.25 As 
described above, the SH2-kinase domain 
linker in Abl contains a PxxP motif and is 
bound by the SH3 domain. The second 
proline residue of the PxxP motif is 
replaced in Abl by Tyr-245, and its phos-
phorylation was predicted to disrupt the 
autoinhibited structure, consistent with 
the high levels of activity observed upon 
phosphorylation of Tyr-245 in Abl.18
Abl Fusion Proteins in Cancer
c-Abl was discovered as the cellular 
homologue of the viral oncoprotein v-Abl 
that is expressed by the Abelson murine 
leukemia virus.36 In humans, Abl kinases 
are involved in a number of chromosomal 
abnormalities in different cancers that 
lead to the expression of fusion proteins, 
but no (activating) point mutations in the 
ABL1 or ABL2 genes have yet been 
identified in human cancers or other dis-
eases. In all human Abl fusion proteins, 
as well as in murine v-Abl, regions 
upstream of the Abl kinase domain are 
replaced by another protein (Fig. 3). The 
fusion partner contributes sequences that 
drive dimerization/multimerization of the 
kinase, which, by itself, was shown to 
trigger Abl activation.37 In general, the 
fusion event leads to a loss of kinase 
autoinhibition by removing the myris-
toylation site and, in some cases, the SH3 
and SH2 domains (Fig. 3).10,19 In addition 
to the gain in tyrosine kinase activity, Abl 
fusion partners trigger the activation of 
the oncogenic pathways. I would like to 
provide a summary of the structure and 
signaling of the most common Abl fusion 
proteins that are expressed in hematologi-
cal malignancies. I will first focus on Bcr-
Abl, as this is by far the most intensively 
studied and best understood among the 
Abl oncoproteins.
Bcr-Abl
The t(9;22)(q34;q11) chromosomal trans-
location that results in the formation of 
the Philadelphia (Ph) chromosome was 
the first consistent chromosomal aberra-
tion linked to human cancer38 (reviewed 
in Rowley39). Seminal work in the fol-
lowing 2 decades showed that the Ph 
chromosome encoded the Bcr-Abl pro-
tein that is formed by the fusion of the 
ABL1 gene (on chromosome 9) and the 
breakpoint cluster region gene (on chro-
mosome 22). The translocation break-
point on chromosome 9 upstream of exon 
2 of the ABL1 gene leads to loss of 
expression of the first exon of ABL1 in 
the Bcr-Abl fusion protein. Within the 
BCR gene, 3 translocation breakpoints 
were mapped.40 This leads to the expres-
sion of proteins with 210 kDa (termed 
Bcr-Abl p210), 185/190 kDa (termed 
Bcr-Abl p185), or rarely 230 kDa (termed 
Bcr-Abl p230) apparent molecular weight 
(Fig. 3; reviewed in Wong and Witte41). 
These different Bcr-Abl fusion proteins 
are expressed in different diseases. p210 
expression is the molecular hallmark of 
chronic myelogenous leukemia (CML).40 
The other major disease in which the Ph 
chromosome is detected are 20% to 30% 
of adult and 2% to 3% of pediatric 
(B-cell) acute lymphoblastic leukemias 
(ALLs). In Ph-positive B-ALL, around 
one-third of patients express p210 and 
around two-thirds express p185. p230 is 
rarely expressed in neutrophilic-CML/
chronic neutrophilic leukemia.42
Molecular Mechanisms of Oncogenic 
Transformation
The expression of the Bcr-Abl fusion 
protein has interrelated consequences. 
First, the Abl kinase domain becomes 
catalytically very active and phosphory-
lates a variety of different substrate pro-
teins. Second, the Bcr-moiety of the 
fusion contributes critical domains and 
sequence motifs that drive activation of 
downstream signaling pathways. Third, 
Bcr-Abl becomes strongly autophosphor-
ylated. Therefore, Bcr-Abl serves as a 
docking scaffold for SH2 and PTB (phos-
photyrosine-binding) domain-containing 
proteins that assemble a multiprotein 
complex from which signaling pathways 
diverge. In contrast to autoinhibited Abl, 
Bcr-Abl was shown to exist in a complex 
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with a limited number of other proteins in 
equimolar stoichiometry and different 
associated enzymatic activities.43
The Coiled-Coil Domain
When comparing the primary structure of 
Bcr-Abl and Abl, it becomes apparent 
that the lack of autoinhibitory N-terminal 
myristoylation may contribute to the con-
stitutive activation of Bcr-Abl (Fig. 3). In 
addition, activation is strongly driven by 
the coiled-coil oligomerization domain 
that is located at the N-terminus of Bcr-
Abl (Fig. 3). Loss-of-function mutants 
have decreased kinase activity and dis-
play impaired transformation.44 Struc-
tural and biophysical work showed 
that the coiled-coil domain is predomi-
nantly forming stable antiparallel homo- 
tetramers.45,46 Targeting the coiled-coil 
domain dimerization interface has been 
successfully attempted using a peptide 
competitor in cell lines and inhibited Bcr-
Abl signaling.47,48 Despite these promis-
ing results, further investigation will have 
to demonstrate whether coiled-coil inhib-
itors work in vivo and if the required 
specificity for Bcr-Abl can be achieved.
Phosphotyrosine 177
The other major known contribution of 
the Bcr-moiety to leukemogenicity of 
Bcr-Abl is a tyrosine residue at amino 
acid position 177 (Tyr-177), which is 
phosphorylated (Fig. 3). Mutation of Tyr-
177 to Phe strongly impaired transforma-
tion in vitro and leukemogenesis in 
mouse models.49,50 Phosphorylated Tyr-
177 binds to the SH2 domain of the adap-
tor protein Grb2, which in turn binds via 
its 2 SH3 domains to a variety of different 
signaling proteins. Among those, binding 
and activation of the guanine nucleotide 
exchange factor Sos1 lead to activation of 
Ras and a variety of downstream effec-
tors, including the mitogen-activated pro-
tein (MAP) kinase pathway. In addition, 
Grb2 binds to Gab2, which is phosphory-
lated strongly at multiple tyrosine resi-
dues in Bcr-Abl–positive cells.51 The Gab 
(Grb2-associated binder) proteins are a 
family of adaptor proteins that have been 
shown to bind different receptor tyrosine 
kinases such as epidermal growth factor 
receptor (EGFR), c-Met, insulin receptor, 
and cytokine- and B-cell receptors.52,53 
Homozygous Gab2 knockout cells are 
severely compromised in Bcr-Abl– 
mediated oncogenic transformation and 
leukemogenesis in a mouse model.54 By 
means of its multiple tyrosine phosphory-
lation sites, Gab2 serves as an assembly 
platform for the tyrosine phosphatase 
SHP2 (PTPN11), the p85α/β regulatory 
subunits of PI3K, phospholipase C-γ, and 
other proteins without (associated) enzy-
matic activities.53 Binding of these 3 pro-
teins is critical for the activation of the 
MAP- and PI3-kinase pathways—2 
major oncogenic pathways being acti-
vated in Bcr-Abl–positive cells.54-56 In 
addition, it was suggested that Gab2 (and 
its complex members) may coordinate 
the binding and activation of the tran-
scription factor STAT5—another critical 
player in Bcr-Abl–dependent leukemo-
genesis—in the cytoplasm.57,58 Targeting 
of Grb2 has been attempted using an SH3 
domain ligand peptidomimetic, which 
was able to induce apoptosis and sup-
press colony formation in semisolid 
medium in Bcr-Abl–expressing cells.59
Figure 3. ABL1 and ABL2 fusions in cancer. Schematic domain representation of the proto-
oncogene products of the ABL1 and ABL2 genes, as well as the known fusion gene products that 
mainly arise through chromosomal translocations. Known phosphorylation sites are indicated. The 
phosphorylation events on Tyr-177 in Bcr-Abl isoforms and Tyr-314 in Etv6-Abl that are discussed 
in more detail are indicated in red. Sizes of the proteins are approximately to scale. Domain 
abbreviations are as follows: TyrK, tyrosine kinase; FABD, F-actin binding; CC, coiled-coil; DH, 
Dbl-homolgy; PH, Pleckstrin-homology; RHOGAP, Rho GTPase-activating protein; WD40, Trp-Asp 
(W-D) terminating domain of ~40 amino acid length; PNT, pointed dimerization domain; RRM, RNA 
recognition motif.
441Abl oncpoproteins: Structure, signaling, targeting / Hantschel MMonographs
Crk Adaptors and STAT5
A large number of signaling pathways 
are activated by Bcr-Abl. In fact, there is 
hardly any pathway that has not been 
described to be influenced in one way or 
the other by Bcr-Abl expression.60,61 In 
contrast, only a few proteins appear to 
be critical for Bcr-Abl–dependent trans-
formation, including Gab2 (see above), 
Myc,62 and CrkL and STAT5.
The Crk family of adaptor proteins is 
among the dominant and best-described 
substrates of Abl and Bcr-Abl.63,64 In 
particular, CrkL binding to Bcr-Abl is 
necessary for oncogenic transforma-
tion,65 whereas CrkII is not. Some of the 
puzzling differences between CrkL and 
CrkII, given their high sequence iden-
tity, were recently explained in an ele-
gant structural analysis by distinct 
intramolecular interactions and accessi-
bility of the SH3 and SH2 domains.66 A 
much more detailed and expert analysis 
on the role of Crk protein downstream of 
Abl kinases is provided in other review 
articles published in this issue.
Another central Bcr-Abl substrate is 
the transcription factor STAT5, which 
was among the first downstream effectors 
shown to be activated in Bcr-Abl–
expressing cells.67 STAT5 is one the few 
proteins that are critical for leukemia ini-
tiation and the very few that are critical 
for leukemia maintenance, therefore 
qualifying as an attractive drug target.68-70 
In addition, the contribution of STAT5 
expression levels to CML progression 
and kinase inhibitor resistance was 
recently demonstrated.71 Unexpectedly, 
STAT5 phosphorylation in Bcr-Abl–
expressing cells is independent of the 
canonical upstream JAK2 kinase. Fur-
thermore, JAK2 was not required for Bcr-
Abl–induced leukemogenesis or STAT5 
activation in different mouse and cellular 
models.72 In addition, the hypothesis that 
STAT5 is a direct substrate of Bcr-Abl 
could be convincingly consolidated.72 
These insights question the proposed tar-
geting of JAK2 using novel, clinically 
approved JAK2 tyrosine kinase inhibitors 
to target therapy-resistant CML. Although 
STAT5 is a very challenging direct drug 
target, as it is a transcription factor and 
devoid of an enzymatic domain that can 
be targeted readily, pimozide, a small 
molecule identified in a screen for inhibi-
tors of STAT5 transcriptional activity, 
decreased survival of CML cells resistant 
to kinase inhibitors.73
Nup214-Abl
In 7% of cases with T-cell acute lympho-
blastic leukemia (T-ALL), the Nup214-
Abl fusion protein is expressed. As in 
Bcr-Abl, only the first exon of ABL1 is 
missing in the Nup214-Abl fusion pro-
tein (Fig. 3). Nup214-Abl is formed by 
the extrachromosomal (episomal) 
amplification of a ~500-kb region of the 
long arm of chromosome 9, which fuses 
the majority of the NUP214 exons to 
ABL1.74 Nup214-Abl localizes in mul-
tiple copies to the nuclear pore complex, 
and this localization is necessary for its 
constitutive kinase activity.75 In mouse 
bone marrow transplantation models, 
Nup214-Abl causes a T-cell leukemia 
with longer latency than Bcr-Abl–
induced myeloid leukemias.75 This is in 
line with the observed milder deregula-
tion of tyrosine kinase activity when 
compared with Bcr-Abl. Likewise, 
Nup214-Abl and Bcr-Abl display differ-
ent in vitro and cellular sensitivities for 
Bcr-Abl tyrosine kinase inhibitors, some 
differences in substrate preference, and 
possibly a distinct set of protein interac-
tion partners leading to different signal-
ing networks. This might explain the 
involvement of these 2 Abl fusions in 
different diseases.76 As the Bcr-Abl 
kinase inhibitors potently inhibited 
Nup214-Abl–expressing cell lines, as 
well as showed activity in a murine 
xenograft model and in primary human 
cells from T-ALL patients, clinical 
investigation in patients with NUP214-
ABL1–positive T-cell malignancies is 
warranted.77
Other Abl Fusions
A number of other chromosomal trans-
location events with ABL1 and ABL2 
lead to fusions with ETV6 (Tel) (t(9;12)
(q34;p13)), EML1 (t(9;14)(q34;q32)), 
ZMIZ1 (t(9;10)(q34;q22.3)), SFPQ (t(1;9) 
(p34;q34)), and RCSD1 (t(1;9)(p24;q34)) 
(reviewed in Cazzaniga et al.78; Fig. 3). 
In addition, in AML cases carrying 
the t(1;12)(q25;p13) translocation, ETV6 
is fused to ABL2.79 Each of these ABL1 
or ABL2 fusions was identified in 1 to 
15 cases of T-ALL, B-ALL, AML, RAEB 
(refractory anemia with excess blasts), 
or MPN (myeloproliferative neoplasms) 
and therefore occurs much less frequently 
than Bcr-Abl or Nup214-Abl fusions. 
In ETV6-ABL1/2, EML1-ABL1, and 
ZMIZ1-ABL1, se quences starting from 
exon 2 of ABL1/2 are included in the 
fusion protein, as in Bcr-Abl and Nup214-
Abl. SFPQ-ABL1 and RCSD1-ABL1 are 
fusions with exon 4 of ABL1, which 
therefore do not express the Abl SH3 and 
SH2 domains (Fig. 3). Most ABL fusion 
partners encode for one or more coiled-
coil regions or a PNT domain that medi-
ates dimerization/multimerization and 
drives constitutive kinase activation, 
in analogy to Bcr-Abl. In ETV6-Abl, 
Tyr-314 was found to serve as a Grb2 
binding site once phosphorylated and 
to have equivalent functions for down-
stream signaling as Tyr-177 in Bcr-Abl 
(Fig. 3).80
Targeting Abl Oncoproteins
The deregulated kinase activity of Bcr-
Abl is necessary for the maintenance of 
CML. Although most of the other dis-
eases in which Abl oncoproteins are 
expressed carry additional genomic 
lesions and are less strictly dependent on 
aberrant Abl kinase activity, Abl is also 
considered an important drug target in 
these diseases. Therefore, inhibition of 
Abl oncoprotein signaling was a rational 
way to target these cancers. I would like 
to present 3 main strategies to inhibit 
signaling by Abl oncoproteins, using 
ATP-competitive, allosteric, or Abl 
pathway inhibitors.
ATP-Competitive Inhibitors
The most direct approach to interfere 
with oncogenic Abl signaling is by using 
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compounds that inhibit kinase activity 
by competing with ATP binding to the 
kinase domain. Due to the large number 
of human kinases (more than 500) and 
the conserved structure of the kinase 
domain, kinases were not considered 
good drug targets until the late 1990s. It 
was thought that specificity might be 
hard to achieve, and due to their impor-
tant functions in normal physiology, 
kinase inhibitors might cause intolerable 
toxicity. The rapid preclinical and clini-
cal development of the Bcr-Abl inhibitor 
imatinib (Gleevec) changed this 
dogma.81 Together with the develop-
ment of humanized monoclonal antibod-
ies targeting the extracellular domains 
of oncogenic receptors, small-molecule 
kinase inhibitors have heralded the era 
of molecular targeted therapies. Today, a 
bit more than 10 years after Food and 
Drug Administration approval of ima-
tinib for the treatment of CML, a signifi-
cant fraction of new drug approvals are 
targeted cancer therapeutics.82
Imatinib inhibits Abl kinase activity 
in the 100-nM concentration range and 
is remarkably specific. In addition to the 
Abl kinases, only a few receptor tyro-
sine kinases (KIT, PDFRA/B, DDR1/2) 
and the oxidoreductase NQO2 are inhib-
ited.83 Administration of imatinib leads 
to durable remissions in the majority of 
CML patients and has dramatically 
improved their overall survival.84 How-
ever, the occurrence of point mutations 
in the Bcr-Abl kinase domain that 
reduces imatinib sensitivity of Bcr-Abl 
is the leading cause of acquired drug 
resistance.85 Today, several dozens of 
mutations in the Abl kinase domain have 
been identified in patients treated with 
imatinib. To overcome this shortcoming, 
nilotinib and dasatinib were developed, 
which both inhibit all common imatinib 
resistance mutations with the exception 
of the T315I gatekeeper mutant. Both 
drugs are more potent inhibitors of Abl 
kinase activity.86,87 Nilotinib has a simi-
lar structure to imatinib and shares its 
binding mode and high specificity. In 
contrast, dasatinib differs from imatinib 
in chemical structure, binding mode, and 
pharmacokinetic properties.88,89 Dasat-
inib has a rather broad specificity and 
inhibits the Src, Tec, Csk, and Eph fami-
lies of tyrosine kinases and several Ser-/
Thr-kinases besides the kinase targets of 
imatinib and nilotinib.83,90,91 Both nilo-
tinib and dasatinib are approved for 
the treatment of imatinib-resistant or 
imatinib-intolerant patients, as well as for 
frontline treatment of CML. Both inhibi-
tors are well tolerated, although a similar 
fraction of patients suffer from more 
severe nonhematological toxicities that 
are distinct among the 2 inhibitors.92,93
A small fraction of patients develop 
resistance against nilotinib or dasatinib 
or have the T315I mutation that is 
pan-resistant to all approved Bcr-Abl 
tyrosine kinase inhibitors. Several inves-
tigational drugs were developed for these 
patients.94 Recently, 2 compounds—
ponatinib (AP24534) and DCC-2036—
were identified that inhibited the T315I 
and wild-type form of Bcr-Abl potently 
and equally well and showed promising 
results in animal models with Bcr-Abl 
T315I.95,96 A phase 2 clinical trial of 
ponatinib showed promising results in 
patients with the T315I mutation.97
Allosteric Targeting of the Myristate 
Pocket and the SH2-Kinase Interface
The N-myristoyl modification of Abl 
binds a deep hydrophobic pocket in the 
C-terminal lobe of the kinase domain, 
which was shown to be a major autoin-
hibitory mechanism (Fig. 1).18,19 Bcr-
Abl is not myristoylated as it lacks the 
first exon of Abl, but it retains the 
myristate binding pocket. Therefore, it 
was proposed that compounds that 
mimic myristate binding could push the 
regulatory interactions toward autoinhi-
bition.19 As a consequence, Bcr-Abl 
activity would be allosterically inhib-
ited. Furthermore, such compounds 
should be able to inhibit imatinib resis-
tance, causing mutations as an alterna-
tive site is being targeted. Indeed, 
GNF-2, which was identified in a screen 
for antagonists of Bcr-Abl–dependent 
cell growth, bound to the myristate 
pocket and potently inhibited Bcr-Abl 
wild-type and resistant forms.98,99 A 
combination treatment of GNF-2 and 
nilotinib was shown to prolong survival 
in a Bcr-Abl T315I mouse model.99 
Therefore, the combination of ATP-
competitive and myristate pocket inhibi-
tors represents an innovative and rational 
way to overcome resistance to either 
agent alone (reviewed in Hantschel23).
A second allosteric targeting site is the 
interface of the SH2 and the kinase 
domain in active Abl. Formation of the 
SH2-kinase domain interface is strictly 
necessary for oncogenicity, as a point 
mutation disrupting the interface was not 
able to induce CML in mice, reduced 
Bcr-Abl kinase activity, and failed to acti-
vate STAT5.33 This strongly highlighted 
the Bcr-Abl SH2-kinase domain interface 
as target for therapeutic intervention. As a 
proof of concept, an engineered high-
affinity SH2 binding protein (Abl SH2 
monobody) was developed to target the 
Bcr-Abl SH2-kinase domain interface. 
This monobody inhibited Bcr-Abl kinase 
activity, abrogated transformation, and 
induced apoptosis in primary human 
CML cells.33 Future work will have to 
demonstrate if the intramolecular domain 
interface that buries substantial surface 
area can be targeted with small molecules 
that could be applied in combination with 
ATP-competitive inhibitors to treat CML 
or related diseases.
Targeting Proximal Signaling/
Downstream Effectors
As CML stem cells do not depend on 
Bcr-Abl expression for their survival and 
are not eradicated by current ATP-com-
petitive inhibitors, a variety of alternative 
targets are being explored to target these 
cells. These approaches have been com-
prehensively covered in excellent recent 
review articles and therefore will not be 
discussed further.100-102 In addition, 
numerous signaling molecules in the Bcr-
Abl signaling network were attempted to 
be inhibited with the hope to overcome 
resistance. A few of the best-studied 
examples are discussed here.
The Src kinases Lyn, Hck, and Fgr are 
required for Bcr-Abl–induced B-ALL in 
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a mouse model.103 Lyn and Hck can 
be overexpressed in imatinib-resistant 
CML patients not carrying Abl kinase 
domain mutations,104 and both kinases 
were shown to phosphorylate the critical 
Tyr-177 residue in Bcr-Abl.105,106 These 
important insights also triggered the 
development of tyrosine kinase inhibi-
tors, such as dasatinib, that simultane-
ously target Abl and Src kinases. 
Although a direct comparison of drugs 
targeting Abl and Src kinases (e.g., dasat-
inib) with a drug of similar potency only 
targeting Abl kinases (nilotinib) has not 
yet been reported in a clinical trial, a 
comparison of different studies with sim-
ilar patient populations and end points 
does not seem to indicate an advantage of 
the additional targeting of Src kinases.
In addition, the tyrosine kinase Jak2 
has been proposed as a critical target in 
CML and a possible kinase that phos-
phorylates Bcr-Abl Tyr-177 based on 
studies in cell lines.107 In contrast, JAK2 
was recently shown to be dispensable for 
Bcr-Abl–dependent leukemia initiation 
and maintenance in vivo.72 In addition, in 
the presence of Bcr-Abl, JAK2 kinase 
inhibitors fail to decrease activation of 
STAT5.72 Independently, combination 
treatments of JAK2 and Bcr-Abl inhibi-
tors in primary cells only identified a very 
narrow therapeutic window, suggesting 
very limited therapeutic potential of 
JAK2-Abl kinase inhibitor combina-
tions.108 Considered together, these 
results suggest that JAK2 inhibitors 
might not be of therapeutic use in CML.
Finally, combinations of imatinib 
with drugs that target signaling path-
ways downstream of Bcr-Abl were 
tested. The Ras-MAPK pathway was 
targeted with Grb2 SH3, farnesyl trans-
ferase (targeting Ras), Raf, MEK, or p38 
inhibitors. Likewise, the PI3K-Akt path-
way was targeted with PI3K or mTOR 
inhibitors. Most combinations showed 
reasonable preclinical results, but clini-
cal trials were not initiated or showed 
toxicity or lack of efficacy for many 
of the combinations, in comparison 
to the exceptional efficacy and safety 
of Bcr-Abl tyrosine kinase inhibitors. 
Furthermore, restoration of Bcr-Abl 
activity by resistance mutations appears 
to be dominant and overrides any addi-
tive or synergistic inhibitory effects of 
the second drug.
General Thoughts on 
Oncogenic Networks and 
Outlook
Expression of Bcr-Abl and other Abl 
oncoproteins leads to a qualitative and, 
in particular, a quantitative change of the 
phosphorylation state of the proteome. 
Bcr-Abl–expressing cell lines are rich 
sources for phosphoproteomics analysis 
and have been extensively character-
ized.51,109-111 Due to the variety of path-
ways that are activated in a Bcr-Abl 
kinase activity-dependent manner, some 
of which were described in more detail 
above, many tyrosine, as well as serine-
threonine, kinases are constitutively 
activated and result in aberrant phos-
phorylation of numerous proteins on 
serine, threonine, and tyrosine residues. 
This fact makes it very difficult to dis-
tinguish direct Bcr-Abl substrates from 
those that are phosphorylated by con-
comitant activation of downstream 
kinases. One may even hypothesize that 
many substrates that Bcr-Abl phosphor-
ylates would never get phosphorylated 
by Abl in “healthy” cells because the 
substrate is localized to a different sub-
cellular site, has a suboptimal phosphor-
ylation consensus sequence, is normally 
quickly dephosphorylated, or its abun-
dance is low. One has to keep in mind 
that Bcr-Abl reaches activity levels for 
prolonged times, which have never been 
observed experimentally for Abl.
With a few exceptions, we know very 
little about the precise biological func-
tions of the multitude of Bcr-Abl 
phosphorylation sites. Particular phos-
phorylation events may seem to make 
sense as they are known to support 
growth, proliferation, inhibition of apop-
tosis, or any other feature that supports or 
is essential for the survival of the tumor 
cell. On the other hand, we may be wit-
nessing the aberrant but nonphysiological 
alteration of phosphorylation events by 
Bcr-Abl expression, which at first sight 
may not make biological sense. Exam-
ples include the activation of negative 
Abl regulators (e.g., phosphatases) or 
growth antagonistic and apoptosis- 
promoting pathways. But the balance is 
important, and as long as the phosphory-
lation event does not interfere with the 
overall survival of the tumor cell, this may 
be tolerated. Another important point to 
consider is that Bcr-Abl expression is a 
somatic pathological event and that Bcr-
Abl–expressing cells did not naturally 
evolve. Therefore, the Bcr-Abl signaling 
network never had to withstand long-term 
selective pressure, which in physiological 
pathways/network evolution gets rid of 
dead-end or nonadvantageous interaction 
partners and signaling mechanisms. We 
have seen the emergence of new technol-
ogies to comprehensively and quantita-
tively measure signaling events in an 
unbiased way over the past decade. 
Together with the easier use of structural 
biology techniques and quick, cheap, and 
easy access to genomics and transcrip-
tomics, we now have the opportunities to 
study cancer cell signaling across oncop-
roteins, diseases, tissues, and so on to 
decipher some of the logic (or illogicality 
if you wish) that underlies the aberrant 
signaling by kinase oncoproteins.
Finally, although great progress in 
treating CML patients with tyrosine 
kinase inhibitors has been made over the 
past decade, there are still pressing clini-
cal problems. These include short-lived 
responses in advanced-phase CML and 
other diseases in which Abl oncopro-
teins are expressed, compound muta-
tions (2 or more mutations in the same 
clone), as well as yet unidentified resis-
tance mechanisms. Most important, 
none of the above-described kinase 
inhibitors is curing patients, as cancer 
stem cells are not being targeted.112 
Therefore, the current clinical guide-
lines suggest indefinite treatment, which 
is associated with problems of adher-
ences and long-term tolerability.113 
Thus, research on Abl kinases is still a 
very active and exciting field of research, 
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and the identification of alternative tar-
geting strategies will certainly be able to 
overcome some of the shortcomings of 
current therapies.
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